Lv11
6 积分 2025-12-26 加入
SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
2小时前
已完结
Acid‐Responsive Transferrin Dissociation and GLUT Mediated Exocytosis for Increased Blood–Brain Barrier Transcytosis and Programmed Glioma Targeting Delivery
2小时前
已完结
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
2小时前
已完结
Dermatologic toxicities of antibody-drug conjugates
2小时前
已完结
JSKN021, an innovative site-specific dual-payload bispecific antibody drug conjugate targeting EGFR and HER3 exhibits potent preclinical activities
6个月前
已关闭
Abstract 5423: Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugate
7个月前
已关闭
Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression
7个月前
已完结
皖公网安备34019202002308
